Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database

Journal of Viral Hepatitis

Volumn 11, Issue 6, 2004, Pages 559-562

  Voirin, N ^a   Trepo C ^b   Miailhes, P ^b   Touraine, J L ^c   Chidiac, C ^d   Peyramond, D ^d   Livrozet, J M ^c   Ritter, J ^c   Chevallier, P ^c   Fabry, J ^a   Allard, R ^e   Vanhems, Philippe ^a  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d CROIX ROUSSE HOSPITAL   (France)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Epidemiology; Hepatitis C virus; HIV; Injection drugs use; Risk groups; Survival

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS ANTIBODY;

ADULT; ARTICLE; CLINICAL OBSERVATION; DATA BASE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FRANCE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REACTION OPTIMIZATION; STATISTICAL ANALYSIS; SURVIVAL; SURVIVAL RATE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FRANCE; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV INFECTIONS; HUMANS; MALE; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS;

EID: 8444248309     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2004.00544.x     Document Type: Article

References (15)

1. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315: 1194-1199.
2. Chene G, Binquet C, Moreau JF et al. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. AIDS 1998; 12: 2313-2320.
3. Palella FJ Jr, Deloria-Knoll M, Chmiel JS et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138: 620-626.
4. Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
5. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15: 1115-1123.
6. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995; 333: 751-756.
7. Grabar S, Pradier C, Le Corfec E et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000; 14: 141-149.
8. Neau D, Trimoulet P, Winnock M et al. Impact of protease inhibitors on intrahepatic hepatitis C virus viral load. AIDS 2001; 15: 1736-1738.
9. Trimoulet P, Neau D, Le Bail B et al. Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. J Med Virol 2002; 67: 143-151.
10. Ragni MV, Bontempo FA. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 1999; 180: 2027-2029.
11. Chung RT, Evans SR, Yang Y et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16: 1915-1923.
12. Macias J, Melguizo I, Fernandez-Rivera FJ et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002; 21: 775-781.
13. Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240-247.
14. Mocroft A, Ledergerber B, Katlama C et al. Changes in AIDS, death rates, and survival after AIDS in the EuroSIDA Study: 1994-2002 (180). Presented at 10th Conference on Retroviruses and Opportunistic Infections, Boston, 2003.
15. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.